Stopped Your GLP-1 Because of Side Effects? What's Next

You stopped because the nausea never lifted, or because a weekend went by where you could not keep water down, or because the diarrhea made an ordinary workday impossible. Stopping a GLP-1 medication because of side effects is a medical decision, not a failure of will. Gastrointestinal intolerance is one of the two most commonly reported reasons↗ people come off semaglutide, tirzepatide and liraglutide — sold under names including Ozempic, Wegovy, Mounjaro, Zepbound and Saxenda — the other being cost.

There are several real routes forward from here. Every one of them runs through a prescribing clinician, not through a website.

Stopping is common, and it is not a verdict on you

These are effective medications that help a great many people, and a great many people also stop taking them. Large population↗, claims↗ and health-record↗ cohorts report that more than half of people prescribed a GLP-1 medication are no longer taking it a year later, with higher discontinuation among people treated for weight than among people treated for type 2 diabetes.

Side effects account for a meaningful share of that. In the trials that supported approval, permanent discontinuation because of adverse events ran at roughly 4 to 5 percent for semaglutide, 4 to 7 percent for tirzepatide, around 10 percent for liraglutide, and around 20 percent for naltrexone–bupropion, each against a lower placebo rate, according to the 2025 Canadian pharmacotherapy guideline update↗. Outside a trial, with less structured support around it, real-world discontinuation runs higher still.

Stopping is also frequently temporary. In a large analysis of insurance claims for adults aged 18 to 64 with type 2 diabetes and a BMI of 25 or above, presented at a 2026 endocrinology meeting↗, among those who stopped, roughly four in ten had restarted within a year and closer to six in ten within two; restart rates in people treated for weight alone were not measured. Restarting is not backsliding. For many people it is the right clinical outcome, and it often goes better the second time because you and your prescriber both know more.

Obesity behaves as a chronic, relapsing condition↗, and Canadian guidance↗ treats medication for it the way it treats medication for blood pressure — as long-term management rather than a course you finish. A treatment you could not tolerate is a treatment that did not suit your body. That is a different sentence from the one most people say to themselves.

Why the side effects happened

GLP-1 is a hormone the gut releases after eating. It signals the brain that enough food has arrived, and it slows the rate at which the stomach empties. These medications deliver an engineered version of that signal at higher and steadier levels than the body produces on its own. Tirzepatide acts on a second gut hormone receptor as well.

Nausea, vomiting, diarrhea and constipation are that mechanism showing up where you can feel it — food sitting in the stomach longer than your body is used to. It is not an allergy, and it is not evidence that you were using the medication wrong.

In the pivotal trial of semaglutide 2.4 mg for weight management↗, gastrointestinal events were reported by roughly three-quarters of participants taking the drug and roughly half of those on placebo. Most were mild or moderate, most settled, and about four percent of the semaglutide group stopped permanently because of them. Symptoms cluster at the start of treatment and around each dose increase↗, and for most people they lessen over weeks to months.

"For most people" is a statistic, not a promise. If you were in the group where the symptoms did not settle, none of that describes you — and none of it means you tried less hard than the people it does describe.

Symptoms that need care now rather than wait-and-see

Some symptoms are not tolerability questions. Contact your physician promptly, or go to an emergency department, for:

• Severe or persistent abdominal pain, particularly pain that goes through to the back and comes with vomiting
• Vomiting you cannot control, or being unable to keep fluids down
• Severe pain in the upper right abdomen, fever, or yellowing of the skin or eyes

Pancreatitis and gallbladder problems are uncommon but recognized events with this class↗, and gallstones become more likely during rapid weight loss by any method. Those are reasons to be seen, not reasons to keep reading.

What the options are after stopping a GLP-1

There are more than two, and none of them is chosen from an article.

Restart lower and move slower

The most consistent finding in the tolerability literature↗ is that gradual, individualized dose escalation reduces both the frequency and the severity of gastrointestinal symptoms, and reduces the number of people who quit. Some people who could not tolerate a standard schedule can tolerate a slower one, with longer intervals between steps.

Stay at a dose below the maximum

The maximum approved dose is not the target for everyone. Canadian guidance↗ is explicit that dosing is individualized and that some people meet their treatment goals below the maximum.

Switch to another medication in the same family

The agents in this class differ in their side-effect profiles, and previous exposure to one is associated with less gastrointestinal intolerance when moving to another. Cross-tolerance is incomplete, though, so a switch normally means restarting low and titrating again rather than matching your old dose. Comparing liraglutide and semaglutide shows what those differences look like in practice.

Change class entirely

Five medications are authorized in Canada↗ for general chronic weight management: liraglutide, naltrexone–bupropion, orlistat, semaglutide and tirzepatide. A sixth, setmelanotide, is authorized only for rare monogenic obesity — Bardet-Biedl syndrome, or biallelic POMC, PCSK1 or LEPR deficiency. Each carries its own tolerability profile rather than an absence of one. Naltrexone–bupropion had a notably higher adverse-event discontinuation rate than the GLP-1 medications in its trials, and orlistat's characteristic effects are gastrointestinal in a different way. Trading one side-effect profile for another is a genuine trade-off, not an upgrade. How semaglutide and naltrexone–bupropion compare goes through one such trade in detail.

Look at what else was pushing you toward stopping

Side effects are often not the only pressure. Cost, insurance limits, supply interruptions and plain fatigue with weekly injections frequently sit alongside them, and a plan that solves only the nausea may not hold. For the coverage side of it, see what insurance does and does not cover.

None of that is a self-service menu. Do not restart, change a dose, switch agents or taper based on anything written here, including this. Bring the list to whoever prescribed it. If there is no longer anyone to bring it to, or you would rather work through it with a practice that handles both routes, The Sleeve Clinic prescribes and co-manages weight-management medication as well as performing sleeve gastrectomy.

What tends to happen after stopping

Weight regain after discontinuation is expected rather than exceptional↗, and improvements in blood sugar, blood pressure and other cardiometabolic markers tend to regress alongside it↗. How much, and how fast, varies considerably between people.

That is the mechanism of an ongoing treatment ending, not a relapse of character. Knowing it in advance is more useful than discovering it three months later. What happens to weight after stopping a GLP-1 covers that pattern in detail.

Where surgery fits, and where it does not

Not tolerating a medication is not, by itself, a reason to have an operation. It is a reason to have a conversation about what comes next, and surgery is one item on that list rather than the end of it.

International guidance↗ recommends metabolic and bariatric surgery for adults with a BMI of 35 kg/m² or higher, and consideration of it between 30 and 34.9 where metabolic disease is present or non-surgical treatment has not produced durable results. Thresholds describe populations. Whether an operation is reasonable for one person depends on health history, other conditions, eating patterns and goals, and takes an individualized assessment rather than a self-check against a list. If a GLP-1 has already brought your weight down, the assessment at The Sleeve Clinic weighs your current BMI together with the highest BMI you have documented and how your weight moved between the two, so a number that fell on medication is read in context rather than on its own. The general eligibility criteria are a starting point for that conversation.

Surgery is also not an escape from side effects. Sleeve gastrectomy permanently changes the stomach, carries operative risk, and commits you to vitamin and mineral supplementation and bloodwork for life↗. Reflux after it is reported across a wide range in the published literature, and weight regain is possible after surgery too. How sleeve gastrectomy works and what lifelong follow-up involves cover both.

If you are still taking a GLP-1 and an operation is under discussion, the delayed stomach emptying these drugs produce matters for anesthesia. The Sleeve Clinic's instruction is that the medication stops before an operation here, and stops at least two weeks beforehand. The 2024 multi-society guidance↗ leaves more room than that, asking the prescribing, surgical and anesthesia teams to weigh the risk together rather than applying a single blanket rule. The clinic's instruction is the more conservative of the two and it is the one that applies to surgery here; for a procedure booked with another team, follow the instruction that team gives you. What that does not mean is stopping a prescription on your own in anticipation of surgery — the date you stop is set with your surgical team once an operation is actually booked.

The Sleeve Clinic is a private-pay practice, and surgery here is not covered by OHIP; what it costs and how financing works is set out separately. A publicly funded bariatric pathway also exists in Ontario, accessed through physician referral. If the medication-versus-surgery question is the one actually on your mind, how the two compare goes into it properly.

Frequently asked questions

Is it dangerous to stop a GLP-1 medication because of side effects?

Stopping is not inherently dangerous, and for some symptoms it is the right call. Tell your prescriber that you stopped and why, rather than simply not refilling — particularly if you also take medication for diabetes or blood pressure, since those may need review as blood sugar and weight change.

Will the side effects go away once I stop?

Gastrointestinal effects generally ease as the medication clears, which takes some weeks. Symptoms that persist, worsen, or were severe to begin with should be assessed rather than waited out.

Does not tolerating the medication mean it failed?

No. It means that agent, at that dose and that titration speed, did not suit you. A slower pace, a lower dose, a different medication in the class, or a different class entirely are separate questions, and your prescriber is the person who can answer them for your situation. Tolerating a medication and getting the result you hoped for are also two different questions. When a GLP-1 stops working takes up the second one.

Can I try the same medication again later?

Many people do, and a slower restart is a recognized approach. That decision belongs to your prescriber, who can weigh what happened the first time against your medical history.

Should I just switch to a different GLP-1?

Possibly, and possibly not. The agents differ in tolerability and in what they are approved for, and switching normally means restarting low and titrating again. It is a prescribing decision rather than a preference.

Does stopping mean surgery is the answer now?

Not automatically. Surgery suits some people and not others, it is permanent, it carries risk, and it commits you to lifelong follow-up. Intolerance to a medication does not predict how someone responds to an operation, because the mechanisms differ. Other options when injections are not working covers the wider set of routes.

About this information

This is general education, not personal medical advice. It cannot tell you whether your medication should change or whether surgery is appropriate for you, because those answers depend on an individualized assessment, and the benefits, risks and alternatives differ from one person to the next. Do not start, stop or adjust a prescription based on what you read here — talk to the clinician who prescribed it. For urgent symptoms, contact your physician or local emergency services. Individual results vary. Consult with Dr. Gmora for a personalized assessment.

The Sleeve Clinic is a private-pay bariatric practice in Toronto, with virtual consultations available across Canada, led by Dr. Scott Gmora, MD FRCSC FACS. Alongside sleeve gastrectomy, the clinic prescribes and co-manages weight-management medication.

If you want to talk it through

Plenty of people reach this point without knowing which of the options above applies to them, and that is a reasonable place to begin a conversation rather than end one. If it would help to work through where you are with someone who does this every day, you are welcome to book a consultation. There is no obligation, and for some people the honest answer is that surgery is not the right next step. Because the clinic prescribes and co-manages weight-management medication as well as performing surgery, a slower restart, a different agent, or staying on medical treatment and leaving an operation out of it are all answers a consultation here can end in — a reader who has come off a GLP-1 and has no interest in surgery still has somewhere to take the question. If you would rather bring a rough number in, the weight-loss calculator gives an estimated range.